Bristar Immunotech Biotechnology Co., LTD
1:45 PM - 2:00 PM (EST), Tuesday, February 7, 2023 ・ Winter Garden
BriSTAR Immunotech Ltd. is a clinical-stage cell therapy company founded in 2018, focusing on developing better T cell therapies for the treatment of cancer and viral infections. We employ two technology platforms, STAR-T and enTCR-T. STAR-T, like CAR-T is HLA-independent, but uses full TCR-signaling complex and capacity to engage and kill cancer cells. EnTCR-T engages a co-stimulatory signaling in addition to the TCR complex for clearing viral infections. Our current pipeline includes product candidates indicated for hematological malignancy, solid tumor as well as viral infections. Our lead product, a dual targeting CD19/CD20 STAR-T candidate, is currently in clinical trial for R/R B cell malignancies.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
China
Year Founded:
2018
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
HXYT-001(CD19/CD20 STAR-T)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
